Skip to main content
Publications
Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-99. doi: 10.1200/JCO.23.00170
Edwards T, Norcross L, Fine J, Martin S, Coulouvrat C, Spears P, Herold CI, Ferrari G, Onwudiwe N. Side effects and impacts of extended adjuvant endocrine therapy: a qualitative study among women with HR+/HER2- breast cancer. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023 Jun; 41(Suppl 16):e12509. doi: 10.1200/JCO.2023.41.16_suppl.e12509
Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, Levy RA, Liu A, Marino R, Meizlik P, Pimenta JM, Sumner K, Tilson H, Connolly MB, Wurst K, Harris J, Quasny H, Juliao P, Roth DA. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis. 2023 Feb;82(2):217-25. doi: 10.1136/ard-2022-222505
Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Dave V, Downey C, Shillington AC, Devgan G, Kirker M, Thakkar S, Katzenstein HM, Bhanegaonkar A, Liu F, Brown J, Sonpavde GP. Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II). Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Francisco, CA. [abstract] J Clin Oncol. 2023 Feb 1; 41(Suppl 4). doi: 10.1200/JCO.2023.41.6_suppl.465
Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.
Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andre F. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2–negative advanced breast cancer from SOLAR-1. J Clin Oncol. 2021 Jun 20;39(18):2005-15. doi: 10.1200/JCO.20.01139
Ogdie A, Mansfield C, Myers K, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh JA. Real-world patient experience and treatment preferences in patients with psoriatic arthritis. Poster presented at the Virtual EULAR 2021 Congress; June 2, 2021. [abstract] Ann Rheum Dis. 2021 Jun; 80(Suppl 1):237. doi: 10.1136/annrheumdis-2021-eular.852
Husni ME, Bozyczko M, Wolin D, Sweeney C, Davenport E, Hass S, Yi E, Hur P, Grinnell-Merrick L. A prospective, longitudinal study to evaluate real-world patient experiences and treatment satisfaction with secukinumab for psoriatic arthritis. Poster presented at the Virtual EULAR 2021 Congress; June 2, 2021. [abstract] Ann Rheum Dis. 2021 Jun; 80(Suppl 1):808-9.
Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Ayele Asfaw A, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4502.
Wyrwicz L, Elimova E, Blum SI, Xiao H, Davenport E, Wang J, Hunter S, Li M, Kondo K, Mohler M. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4066. doi: 10.1200/JCO.2021.39.15_suppl.4066
Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057
Zeng X, Leng X, Wei K, Tang WM, Tang CH, Tunceli K, Aggarwal J, Ramey D, Lozano F, Doshi I, Macahilig C, Odak S, Johnson K. Results from a cross-sectional, observational study to assess inadequate pain relief in patients with knee and/or hip osteoarthritis in China. Poster presented at the 2020 Virtual Annual European Congress of Rheumatology (EULAR); June 5, 2020. [abstract] Ann Rheum Dis. 2020 Jun; 79(Suppl 1):812-3. doi: 10.1136/annrheumdis-2020-eular.5813
Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S, Abad J, Duran-Cantolla J, Cabriada V, Mediano O, Masdeu MJ, Alonso ML, Masa JF, Barcelo A, de La Pena M, Mayos M, Coloma R, Montserrat JM, Chiner E, Perello S, Rubinos G, Minguez O, Pascual L, Cortijo A, Martinez D, Aldoma A, Dalmases M, McEvoy RD, Barbe F, Spanish Sleep Network. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Resp Med. 2020 Apr;8(4):359-67. doi: 10.1016/S2213-2600(19)30271-1
Olivieri M, Murgia N, Carsin AE, Heinrich J, Benke G, Bono R, Corsico AG, Demoly P, Forsberg B, Gislason T, Janson C, Jogi R, Leynaert B, Rovira JM, Norback D, Nowak D, Pascual S, Pin I, Probst-Hensch N, Raherison C, Sigsgaard T, Svanes C, Toren K, Urrutia I, Weyler J, Jarvis D, Zock JP, Verlato G. Effects of smoking bans on passive smoking exposure at work and at home. The European Community respiratory health survey. Indoor Air. 2019 Jul;29(4):670-9. doi: 10.1111/ina.12556
Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre M, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(15_Suppl).
Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox, MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drilon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Poster presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(2019):6602.
Price M, Ravelo A, Sae-Hau M, Torney PA, Gonzalez V, Weiss ES, Mansfield C, Mange B, Comenencia Ortiz E, Masaquel A, Lamont Dawson K. Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey. Poster presented at the 2019 ASCO Annual Meeting; May 2019. [abstract] J Clin Oncol. 2019 May 26; 37(15_suppl):e18198. doi: 10.1200/JCO.2019.37.15_suppl.e18198
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomised, controlled study in biologic-naÏve subjects with active psoriatic arthritis. Poster presented at the EULAR 2018 Annual European Congress of Rheumatology; June 13, 2018. Amsterdam, The Netherlands. [abstract] Ann Rheum Dis. 2018 Jun 12; 77(Suppl 2):A1598. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.1136/annrheumdis-2018-eular.3139
Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174
Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez Salas N, Martin M, Alonso V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guasch I, Montagut Viladot C, Lopez-Lopez C, Canas MA, Declara IM, Garcia-Albeniz X. Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial. Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; 36(2018):e3518.
Panella P, Casas M, Donaire‐Gonzalez D, Garcia‐Esteban R, Robinson O, Valentín A, Gulliver J, Momas I, Nieuwenhuijsen M, Vrijheid M, Sunyer J. Ultrafine particles and black carbon personal exposures in asthmatic and non-asthmatic children at school age. Indoor Air. 2017 Sep;27(5):891-9. doi: 10.1111/ina.12382
Norback D, Zock JP, Plana E, Heinrich J, Tischer C, Jacobsen R, Sunyer J, Kunzli N, Villani S, Olivieri M, Verlato G, Soon A, Schlunssen V, Gunnbjornsdottir MI, Jarvis D. Building dampness and mould in European homes in relation to climate, building characteristics and socio-economic status: the European Community Respiratory Health Survey ECRHS II. Indoor Air. 2017 Sep;27(5):921-32. doi: 10.1111/ina.12375
Telfort J, Trivedi MS, Yi HS, Colbeth H, Vanegas A, Vargas J, Sandoval R, Wood J, Dimond J, Finkelstein J, Kukafka R, Crew KD. Implementing decision support for breast cancer chemoprevention in primary care. J Clin Oncol. 2017 May;35(15 Suppl):e13038. doi: 10.1200/JCO.2017.35.15_suppl.e13038
Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, Uhlig T, van Vollenhoven R, Jacques P, Detert J, Canas da Silva J, Scire CA, Berghea F, Carmona L, Pentek M, Keat A, Boonen A. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Ann Rheum Dis. 2017 Jan;76(1):126-32. doi: 10.1136/annrheumdis-2016-209202
Maurel J, Fernandez-Martos C, Martin-Richard M, Alonso V, Mendez JC, Salud A, Pericay C, Aparicio J, Gallego J, Carmona A, Casado E, Manzano H, Horndler C, Rubini M, Cuatrecasas M, Garcia-Albeniz X, Feliu J. Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]. Poster presented at the 2016 ASCO Annual Meeting; January 23, 2016. Chicago, IL. [abstract] J Clin Oncol. 2016 Feb; 34(4_Suppl):583. doi: 10.1200/jco.2016.34.4_suppl.583
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015 Aug 10;33(23):2516-22.
Guerra S, Halonen M, Vasquez MM, Spangenberg A, Stern DA, Morgan WJ, Wright AL, Lavi I, Tares L, Carsin AE, Dobano C, Barreiro E, Zock JP, Martinez-Moratalla J, Urrutia I, Sunyer J, Keidel D, Imboden M, Probst-Hensch N, Hallberg J, Melen E, Wickman M, Bousquet J, Belgrave DCM, Simpson A, Custovic A, Anto JM, Martinez FD. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Resp Med. 2015 Aug;3(8):613-20. doi: 10.1016/S2213-2600(15)00196-4
Stenehjem DD, Tyczynski JE, Unni SK, Bauer H, Sainski A, Deka R, Shauehamer M, Gutierrez LP, Kaye JA, Telford C, Brixner DI, Biskupiak DI. Evaluation of BRCA mutation (BRCAm) testing patterns, clinical characteristics and overall survival (OS) in breast cancer (BC) patients over a 20-year period. J Clin Oncol. 2015 May 29;33(15_suppl):e12518. doi: 10.1200/jco.2015.33.15_suppl.e12518